We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Veracyte (VCYT - Free Report) ten years ago? It may not have been easy to hold on to VCYT for all that time, but if you did, how much would your investment be worth today?
Veracyte's Business In-Depth
With that in mind, let's take a look at Veracyte's main business drivers.
Headquartered in South San Francisco, CA, Veracyte, Inc. is a global diagnostics company that provides clinicians with valuable insights to diagnose and treat cancer. The company offers advanced genomic tests that leverage scientific, clinical and machine learning expertise. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer) and Decipher Bladder (bladder cancer), with additional tests in development. The company also has operations in San Diego, California, Austin, Texas and Haifa, Israel.
These tests improve diagnostic, prognostic, predictive and treatment decisions, helping patients avoid unnecessary procedures and reduce the time needed to find appropriate treatment options. In the United States, Veracyte offers its tests through central laboratories while making them accessible worldwide through collaborations with local labs. Outside the United States, the company provides its Prosigna test to laboratories and hospitals that can perform the test locally as an in vitro diagnostic (IVD) assay. Veracyte also plans to offer Prosigna as a laboratory-developed test (LDT) in 2026.
The company recognizes revenues from three sources:
Testing revenues (96% of total revenues in 2025, up 3.2% from 2024): Upon delivery of the test results, the company bills for testing services considering factors such as payer reimbursement history, contracts and coverage.
Product revenues (3% of 2025 revenues; flat): Includes revenues from Prosigna breast cancer assay, the nCounter Analysis System (acquired from Nanostring Technologies, Inc. in 2019) and related diagnostic kits.
Biopharmaceutical and other revenues (1% of 2025 revenues; down 200%): Includes revenues from licensing or providing access to the company’s assets and services, including testing and contract manufacturing.
The company’s 2021 acquisition of Decipher Biosciences expanded its genomic testing menu into urologic cancers and provided Decipher GRID (Genomic Resource for Intelligent Discovery) — a platform and database that helps drive biopharmaceutical partnerships, key opinion leaders (KOL) engagement and pipeline development in urologic cancers.
Bottom Line
While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Veracyte ten years ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in May 2016 would be worth $8,560.84, or a gain of 756.08%, as of May 25, 2026, and this return excludes dividends but includes price increases.
In comparison, the S&P 500's gained 264.15% and the price of gold went up 253.75% over the same time frame.
Looking ahead, analysts are expecting more upside for VCYT.
Veracyte continues to scale its core testing franchise, with Decipher Prostate and Afirma driving growth through broader physician adoption and steady evidence generation. First-quarter 2026 results supported this view and led management to raise full-year revenue expectations while keeping investment plans intact. Workflow upgrades are reducing Afirma no-result rates, which supports access and helps expand operating leverage. Management is also preparing two new launches, Prosigna LDT and TrueMRD, which could widen the platform into breast and bladder recurrence settings over time. These positives are balanced by execution risk as the company scales launches, the revenue reset after the Veracyte SAS exit, and competitive and macro conditions that can influence payer behavior, costs and testing demand in the coming quarters.
The stock has jumped 31.17% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 3 higher, for fiscal 2026; the consensus estimate has moved up as well.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Veracyte (VCYT - Free Report) ten years ago? It may not have been easy to hold on to VCYT for all that time, but if you did, how much would your investment be worth today?
Veracyte's Business In-Depth
With that in mind, let's take a look at Veracyte's main business drivers.
Headquartered in South San Francisco, CA, Veracyte, Inc. is a global diagnostics company that provides clinicians with valuable insights to diagnose and treat cancer. The company offers advanced genomic tests that leverage scientific, clinical and machine learning expertise. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer) and Decipher Bladder (bladder cancer), with additional tests in development. The company also has operations in San Diego, California, Austin, Texas and Haifa, Israel.
These tests improve diagnostic, prognostic, predictive and treatment decisions, helping patients avoid unnecessary procedures and reduce the time needed to find appropriate treatment options. In the United States, Veracyte offers its tests through central laboratories while making them accessible worldwide through collaborations with local labs. Outside the United States, the company provides its Prosigna test to laboratories and hospitals that can perform the test locally as an in vitro diagnostic (IVD) assay. Veracyte also plans to offer Prosigna as a laboratory-developed test (LDT) in 2026.
The company recognizes revenues from three sources:
Testing revenues (96% of total revenues in 2025, up 3.2% from 2024): Upon delivery of the test results, the company bills for testing services considering factors such as payer reimbursement history, contracts and coverage.
Product revenues (3% of 2025 revenues; flat): Includes revenues from Prosigna breast cancer assay, the nCounter Analysis System (acquired from Nanostring Technologies, Inc. in 2019) and related diagnostic kits.
Biopharmaceutical and other revenues (1% of 2025 revenues; down 200%): Includes revenues from licensing or providing access to the company’s assets and services, including testing and contract manufacturing.
The company’s 2021 acquisition of Decipher Biosciences expanded its genomic testing menu into urologic cancers and provided Decipher GRID (Genomic Resource for Intelligent Discovery) — a platform and database that helps drive biopharmaceutical partnerships, key opinion leaders (KOL) engagement and pipeline development in urologic cancers.
Bottom Line
While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Veracyte ten years ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in May 2016 would be worth $8,560.84, or a gain of 756.08%, as of May 25, 2026, and this return excludes dividends but includes price increases.
In comparison, the S&P 500's gained 264.15% and the price of gold went up 253.75% over the same time frame.
Looking ahead, analysts are expecting more upside for VCYT.
Veracyte continues to scale its core testing franchise, with Decipher Prostate and Afirma driving growth through broader physician adoption and steady evidence generation. First-quarter 2026 results supported this view and led management to raise full-year revenue expectations while keeping investment plans intact. Workflow upgrades are reducing Afirma no-result rates, which supports access and helps expand operating leverage. Management is also preparing two new launches, Prosigna LDT and TrueMRD, which could widen the platform into breast and bladder recurrence settings over time. These positives are balanced by execution risk as the company scales launches, the revenue reset after the Veracyte SAS exit, and competitive and macro conditions that can influence payer behavior, costs and testing demand in the coming quarters.
The stock has jumped 31.17% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 3 higher, for fiscal 2026; the consensus estimate has moved up as well.